Cipla’s arm recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution

25 Oct 2022 Evaluate

Cipla’s US-based arm is recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution, which is used to help control the symptoms of chronic obstructive pulmonary disease (COPD). The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’.

The affected lot has been produced by Cipla at its Madhya Pradesh based plant. Cipla commenced the Class II recall in the US on September 30, 2022. As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1347.50 1.80 (0.13%)
26-Feb-2026 12:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1774.00
Dr. Reddys Lab 1309.90
Cipla 1347.50
Zydus Lifesciences 929.00
Lupin 2308.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×